With the expected results, there is no doubt all will be done post haste as with the media blitz I expect after results there is no way anybody will be able to downplay Brilacidin.
As to the competitors whose names end with mab, that stands for monoclonal antibody (mAB).
From what I have read, there are issues with these both in safety and efficacy for anything but mild to moderate symptoms and mainly are used very early in treatment. Suspect as to efficacy if virus already advanced in patient.
Not saying they don't have their place, but I would rather go with a therapeutic that absolutely kills the virus and has no safety issues.
Like our chances with Brilacidin more and more every day.
News 
Market Data 
Discover 
AI
